Innovation Through Collaboration Positions Precision BioLogic as a Leader in Hemostasis Diagnostics and Research

Leading the Charge in Hemostasis Diagnostics

Precision BioLogic Inc., a renowned developer in the realm of diagnostic products for hemostasis, is making noticeable waves in the clinical and research sectors due to its robust collaborations with entities like Affinity Biologicals and George King Bio-Medical. This synergy has not only enhanced its product offerings but has also caught the attention of clinicians and researchers across the globe, making Precision BioLogic a name synonymous with innovation.

Recent Innovations and Developments

Since the announcement of its expanded applicability for the CRYOcheck™ Chromogenic Factor VIII Assay last fall, especially in relation to new hemophilia therapies such as Mim8—a next-generation bispecific antibody aimed at treating Hemophilia A—Precision BioLogic has seen a surge in inquiries about its groundbreaking work. The recent submission by Novo Nordisk of Mim8 to the FDA has only added to the urgency and interest surrounding these products.

Paul Empey, President and CEO of Precision BioLogic, shared insights from their participation at the ISTH 2026 conference in Paris. They received numerous inquiries regarding their bovine-derived chromogenic Factor VIII assay. This innovative assay is capable of measuring Factor VIII accurately—not only in the presence of extended half-life FVIII replacement products but also new bispecific antibodies that mimic FVIIIa. Empey emphasized the growing awareness regarding the necessity of chromogenic assays, affirming their commitment to ensure that coagulation laboratories are well-prepared to deliver precise results.

The company’s research capabilities were showcased prominently at ISTH, where they presented two scientific posters now available on their website:
1. An automated test to detect lupus anticoagulant resistant to anticoagulants, including DOACs and oral FXI inhibitors.
2. The impacts of heat-stable Factor VIII mimetics and substitution therapies on inhibitor titers using a modified Nijmegen-Bethesda test across various bovine chromogenic FVIII assays.

Following ISTH, Precision BioLogic's team attended ADLM 2026 in Anaheim, California, to present Affinity Biologicals' production capacities and its tailored solutions. This was succeeded by participation in the Bleeding Disorders Conference held in Orlando, Florida, where George King Bio-Medical engaged with affected individuals, healthcare professionals, stakeholders, and researchers to discuss the critical role of plasma donation in advancing research, diagnosis, and treatment.

Building a Future in Hemostasis

As the summer of activity winds down, the momentum of innovation at Precision BioLogic remains steadfast. With continuous collaboration among its three operational arms, the company strives to bring reliable products, rapid services, and significant innovations to the global hemostasis community.

Precision BioLogic's dedication to evolving the field of hemostasis is evidenced in their comprehensive portfolio. They design, produce, and market the CRYOcheck™ line of frozen products utilized by medical professionals internationally for diagnosing coagulation disorders. The acquisition of Affinity Biologicals in November 2018 further bolstered their position as a primary manufacturer of products pivotal to thrombosis and hemostasis research and diagnostics. More recently, acquiring George King Bio-Medical in October 2025 enhanced ties to the bleeding disorders community and strengthened their efforts in propelling hemostasis diagnostics and research forward.

For individuals seeking more details about Precision BioLogic, their offerings, and the innovations shaping the future of hemostasis diagnostics, comprehensive information is available on their official website: www.precisionbiologic.com.

In summary, Precision BioLogic stands at the forefront of hemostasis diagnostics, consistently innovating and developing solutions that address the complexities of bleeding disorders, thereby enhancing patient care worldwide.